NCT03652974View on ClinicalTrials.gov

Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

September 6, 2018

Primary Completion Date

August 30, 2021

Study Completion Date

August 30, 2021

Conditions
Schizophrenia
Interventions
DRUG

sodium valproate with Clozapine

sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia

DEVICE

modified electroconvulsive therapy(MECT) with Clozapine

modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia

DRUG

amisulpride with Clozapine

amisulpride may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia

DRUG

placebo with Clozapine

placebo may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia

Trial Locations (1)

200030

Shanghai Mental Health Center, Shanghai

All Listed Sponsors
collaborator

Shanghai Pudong New Area Mental Health Center

UNKNOWN

collaborator

The Affiliated Brain Hospital of Guangzhou Medical University

UNKNOWN

lead

Shanghai Mental Health Center

OTHER

NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy | Biotech Hunter | Biotech Hunter